184 related articles for article (PubMed ID: 27019957)
1. Clinical Exposure Boost Predictions by Integrating Cytochrome P450 3A4-Humanized Mouse Studies With PBPK Modeling.
Zhang J; Heimbach T; Scheer N; Barve A; Li W; Lin W; He H
J Pharm Sci; 2016 Apr; 105(4):1398-404. PubMed ID: 27019957
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
3. Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates.
Umehara KI; Huth F; Won CS; Heimbach T; He H
Biopharm Drug Dispos; 2018 Mar; 39(3):152-163. PubMed ID: 29451681
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
6. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M; Sychterz C; Perera V; Merali S; Palmisano M; Templeton IE; Gaohua L
Clin Pharmacol Ther; 2023 Oct; 114(4):922-932. PubMed ID: 37467157
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Colbers A; Greupink R; Litjens C; Burger D; Russel FG
Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
[TBL] [Abstract][Full Text] [Related]
9. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
10. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
12. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.
Xia B; Barve A; Heimbach T; Zhang T; Gu H; Wang L; Einolf H; Alexander N; Hanna I; Ke J; Mangold JB; He H; Sunkara G
Eur J Pharm Sci; 2014 Oct; 63():103-12. PubMed ID: 25008118
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
15. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
[TBL] [Abstract][Full Text] [Related]
17. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
[TBL] [Abstract][Full Text] [Related]
18. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
Mano Y; Sugiyama Y; Ito K
J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
[TBL] [Abstract][Full Text] [Related]
19. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Xu R; Ge W; Jiang Q
Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492
[TBL] [Abstract][Full Text] [Related]
20. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
